This is the use of genetic profiles to identify the selected patients who have the known druggable targets, such as activation of PIK3CA in 34–56% of HNSCC patients and HRAS mutation identified in 5% of HNSCC patients [7]. The gene discussed is PIK3CA; the disease is head and neck squamous cell carcinoma.